Use of Complementary and Alternative Medicine among People with Multiple Sclerosis in the Nordic Countries
Table 3
Overview of conventional modalities combined with CAM treatment among people with MS in the Nordic countries.
Conventional modality
Denmark ()
Norway ()
Sweden ()
Finland ()
Iceland ()
(%)
OR
(CI)
(%)
OR
(CI)
(%)
OR
(CI)
(%)
OR
(CI)
(%)
OR
(CI)
Physical therapy
582
(60.2)
1.66
(1.29–2.12)+
157
57.7
1.59
(1.18–2.15)+
104
(36.1)
1
148
(48.3)
1.33
(0.99–1.80)
75
(53.9)
1.49
(1.04–2.14)+
Prescription medicine
567
(58.6)
1.35
(1.06–1,71)+
118
43.4
1
173
(60.1)
1.38
(1.03–1.84)+
226
(73.8)
1.70
(1.29–2.24)+
81
(58.3)
1.30
(0.94–1.90)
Non prescription medicine
492
(50.9)
2.07
(1.40–3.06)+
87
31.9
1.30
(0.83–2.04)
120
(41.7)
1.70
(1.11–2.62)+
121
(39.5)
1.61
(1.05–2.48)+
34
(24.5)
1
Conventional massage
145
(15.0)
1.35
(0.89–1.05)
30
11.0
1
73
(25.3)
2.29
(1.45–3.62)+
79
(25.8)
2.34
(1.49–3.67)+
27
(19.4)
1.76
(1.00–3.07)+
Therapeutic horseback riding
138
(14.3)
6.59
(2.07–20.99)+
7
2.6
1.19
(0.30–4.68)
12
(4.2)
1.93
(0.53–6.95)
14
(4.6)
2.11
(0.59–7.49)
3
(2.2)
1
Psychology/ conventional psycho therapy
105
(10.9)
1.63
(0.97–2.74)
18
6.6
1
26
(9.0)
1.36
(0.73–2.54)
23
(7.5)
1.13
(0.60–2.14)
12
(8.6)
1.30
(0.61–2.78)
Chiropractics
73
(7.5)
3.84
(1.65–8.91)+
33
12.1
6.18
(2.55–14.99)+
13
(4.5)
2.30
(0.86–6.13)
6
(2.0)
1
11
(7.9)
4.06
(1.46–11.13)+
Occupational therapy
24
(2.5)
7.13
(0.96–52.95)
14
5.1
14.82
(1.93–113.94)+
1
(0.3)
1
14
(4.6)
13.17
(1.72–100.84)+
12
(8.6)
24.86
(3.20–193.14)+
Others (hot water exercise, electrical stimulation, and laser therapy)
14
(1.4)
1
7
2.6
1.78
(0.71–4.45)
8
(2.8)
1.92
(0.79–4.62)
7
(2.3)
1.58
(0.63–3.95)
6
(4.3)
2.98
(1.12–7.90)+
No conventional treatment
102
(10.5)
1.11
(0.72–1.71)
50
18.4
1.93
(1.19–3.15)+
51
(17.7)
1.86
(1.15–3.03)+
29
(9.5)
1
20
(14.4)
1.51
(0.83–2.77)
“+”signifies that the prevalence is significantly higher than the lowest prevalence. Significance has been determined by interpretation of the 95% confidence intervals (CIs) (if 1 is contained in the CI, ).
